X4 Pharmaceuticals, Inc.

NasdaqCM:XFOR Stok Raporu

Piyasa değeri: US$87.5m

X4 Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 3/4

X4 Pharmaceuticals' CEO is Paula Ragan, appointed in Jul 2014, has a tenure of 10.33 years. total yearly compensation is $2.04M, comprised of 30.3% salary and 69.7% bonuses, including company stock and options. directly owns 0.61% of the company’s shares, worth $532.39K. The average tenure of the management team and the board of directors is 3.6 years and 5.7 years respectively.

Anahtar bilgiler

Paula Ragan

İcra Kurulu Başkanı

US$2.0m

Toplam tazminat

CEO maaş yüzdesi30.3%
CEO görev süresi10.3yrs
CEO sahipliği0.6%
Yönetim ortalama görev süresi3.6yrs
Yönetim Kurulu ortalama görev süresi5.7yrs

Son yönetim güncellemeleri

Recent updates

X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data

Jul 02

Is X4 Pharmaceuticals (NASDAQ:XFOR) Weighed On By Its Debt Load?

Mar 26
Is X4 Pharmaceuticals (NASDAQ:XFOR) Weighed On By Its Debt Load?

Is X4 Pharmaceuticals (NASDAQ:XFOR) A Risky Investment?

Apr 19
Is X4 Pharmaceuticals (NASDAQ:XFOR) A Risky Investment?

Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Too Much Debt?

Oct 07
Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Too Much Debt?

X4 Pharmaceuticals: Upcoming Catalysts

Sep 19

X4 Pharma to focus resources on lead drug candidate, cut workforce by about 20%

Jul 20

X4 Pharmaceuticals to raise $55M in stock and warrants offering, debt facility amended

Jul 01

X4 Pharma: Late Stage Nanocap Targeting Rare Diseases

Aug 03

Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Debt Sensibly?

Jun 22
Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Debt Sensibly?

X4 Pharmaceuticals EPS misses by $0.44

May 06

How Many X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Shares Do Institutions Own?

Mar 16
How Many X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Shares Do Institutions Own?

X4 Pharmaceuticals EPS misses by $0.12

Nov 05

CEO Tazminat Analizi

Paula Ragan'un ücretlendirmesi X4 Pharmaceuticals'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

US$18m

Mar 31 2024n/an/a

-US$129m

Dec 31 2023US$2mUS$620k

-US$101m

Sep 30 2023n/an/a

-US$111m

Jun 30 2023n/an/a

-US$131m

Mar 31 2023n/an/a

-US$96m

Dec 31 2022US$4mUS$583k

-US$96m

Sep 30 2022n/an/a

-US$103m

Jun 30 2022n/an/a

-US$102m

Mar 31 2022n/an/a

-US$100m

Dec 31 2021US$2mUS$562k

-US$103m

Sep 30 2021n/an/a

-US$85m

Jun 30 2021n/an/a

-US$82m

Mar 31 2021n/an/a

-US$78m

Dec 31 2020US$3mUS$543k

-US$62m

Sep 30 2020n/an/a

-US$55m

Jun 30 2020n/an/a

-US$55m

Mar 31 2020n/an/a

-US$53m

Dec 31 2019US$2mUS$492k

-US$53m

Sep 30 2019n/an/a

-US$55m

Jun 30 2019n/an/a

-US$46m

Mar 31 2019n/an/a

-US$40m

Dec 31 2018US$921kUS$380k

-US$36m

Tazminat ve Piyasa: Paula's total compensation ($USD2.04M) is above average for companies of similar size in the US market ($USD655.65K).

Tazminat ve Kazançlar: Paula's compensation has been consistent with company performance over the past year.

CEO

Paula Ragan (54 yo)

10.3yrs

Görev süresi

US$2,044,761

Tazminat

Dr. Paula Ragan, Ph D., is Member of Advisory Board of Tippingpoint Biosciences, Inc. Dr. Ragan serves as an Independent Director of CAMP4 Therapeutics Corporation since May 2019. She is a Founder of X4 Ph...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Paula Ragan
CEO, President & Director10.3yrsUS$2.04m0.61%
$ 532.4k
Adam Mostafa
CFO, Treasurer & Corporate Secretary6.2yrsUS$1.15mVeri yok
Christophe Arbet-Engels
Chief Medical Officer1.3yrsUS$1.64mVeri yok
Richard Peters
Founderno dataVeri yokVeri yok
Renato Skerlj
Founderno dataVeri yokVeri yok
Keith Flaherty
Founder & Member of Corporate Advisory Boardno dataVeri yokVeri yok
Mary DiBiase
Chief Operating Officer3.2yrsUS$1.84m0.27%
$ 234.6k
Arthur Taveras
Chief Scientific Officer4yrsVeri yok0.23%
$ 201.4k
Robert Arbeit
Senior Vice President of Clinical Development and Translational Researchno dataVeri yokVeri yok
Mark Baldry
Chief Commercial Officer2yrsVeri yok0.029%
$ 25.2k

3.6yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim: XFOR's management team is considered experienced (3.6 years average tenure).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Paula Ragan
CEO, President & Director10.3yrsUS$2.04m0.61%
$ 532.4k
Keith Flaherty
Founder & Member of Corporate Advisory Board8.6yrsVeri yokVeri yok
Michael Wyzga
Independent Chairman of the Board6.3yrsUS$199.34k0.045%
$ 39.8k
Gary Bridger
Director5.7yrsUS$147.05k0.031%
$ 26.8k
David W. McGirr
Independent Director7.2yrsUS$166.05k0.031%
$ 26.8k
Alison Lawton
Independent Director4.1yrsUS$154.55k0.031%
$ 26.8k
William Aliski
Independent Director5.2yrsUS$165.05k0.031%
$ 26.8k
Michael Vasconcelles
Member of Corporate Advisory Board8.6yrsVeri yokVeri yok
Robert Woods
Independent Director1.1yrsUS$91.83kVeri yok
Murray Stewart
Director5.7yrsUS$90.08k0.087%
$ 76.0k
Francoise de Craecker
Independent Director3.1yrsUS$152.05k0.031%
$ 26.8k

5.7yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: XFOR's board of directors are considered experienced (5.7 years average tenure).